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Editorial

Learning the hard way: clinical trials in
juvenile idiopathic arthritis
Roberta A Berard,1 Ronald M Laxer2
There have been unprecedented advances
in the treatments and outcomes reported
for patients living with juvenile idiopathic
arthritis (JIA) over the last 20 years. The
future direction of care with multinational
collaborations (Paediatric Rheumatology
International
Trials
Organisation
(PRINTO),
Pediatric
Rheumatology
Collaborative Study Group (PRCSG),
Childhood Arthritis and Rheumatology
Research Alliance) and advances in precision medicine will undoubtedly continue
to revolutionise our approach to diagnosis, treatment and perhaps ultimately
cure of JIA. In Annals of the Rheumatic
Diseases, Brunner et al report on the use
of subcutaneous golimumab for children
with active polyarticular course JIA.1 This
trial, no doubt associated with immense
direct and indirect costs, produced negative results, as it did not achieve its primary
end point. Despite this, there is widespread international opinion that golimumab, like other tumour necrosis factor
(TNF) inhibitors, is effective and should
be added to the therapeutic armamentarium for children with JIA. We must
reflect on this outcome as we consider
further studies with new agents in the
treatment of children with JIA.
To date, three trials of anti-TNF agents
(etanercept, infliximab and adalimumab),2–4
one of a selective T cell costimulation
modulator (abatacept),5 and an interleukin-6 receptor inhibitor6 (tocilizumab)
have shown efficacy and safety in the treatment of polyarticular course JIA in spite of
the fact that primary end point of efficacy
was not met in the infliximab trial. Amarilyo et al7 published a meta-analysis of
randomised withdrawal trials which evaluated the five separate trials (abatacept,5
adalimumab,8 anakinra,9 etanercept10 and
tocilizumab6) all versus placebo. There were
no statistical differences among biological
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agents for efficacy or safety. The parallel
design infliximab trial published in 2007
failed to meet the primary efficacy end
point of American College of Rheumatology Pediatric 30 Criteria (ACRPed30)
at week 14 of infliximab (3 mg/kg) versus
placebo.3 Several factors including inadequate infliximab dosing, too brief placebo
treatment phase and higher-than-expected
placebo-response rate may have contributed to these negative results. Concerns
regarding this study, some of which we raise
again 10 years later, were addressed in an
accompanying editorial.11 Subsequently,
infliximab monotherapy was shown to be
effective in the aggressive combination drug
therapy in very early polyarticular juvenile
idiopathic arthritis (ACUTE-JIA trial),12 a
randomised open-label trial that compared
methotrexate, methotrexate/sulfasalazine/
hydroxychloroquine (COMBO) and infliximab (3–5 mg/kg) in disease-modifying
antirheumatic drug-naive patients. At week
54, ACRPed75 was achieved in 100% on
infliximab, 65% on COMBO and 50% on
methotrexate monotherapy, p<0.0001.
Furthermore, patients on infliximab
remained in a state of inactive disease for a
longer duration (6 months) than the other
two treatment arms (3 months for COMBO
and 1 month for methotrexate). Despite the
initial negative trial, infliximab continues to
be used in clinical practice with effectiveness reported similar to the other biological
agents.13
There are inherent challenges in the
study of treatment efficacy in children
and in particular concerning rare diseases
such as JIA.11 14–16 There are requirements
from the medical community, pharmaceutical industry and regulatory agencies that
have an ethical responsibility to design,
conduct and report on high-quality studies
of medicines in children. To minimise the
number of children exposed to placebo
while providing adequate recruitment,
the three-part placebo-controlled, doubleblind, randomised withdrawal design17
has been used in several trials in patients
with JIA. This trial design tends to overestimate the effect of the trial agent, as
only those who have an initial response
proceed to the blinded withdrawal phase.
Theoretically, this design should be limited
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to drugs with short half-lives that will not
lead to carry-over effects; otherwise the
time of the second phase would need to
be increased, thus negating the benefit of
this trial design.
In the current golimumab study,
members of PRINTO and PRCSG report
on the use of golimumab in polyarticular
course JIA resistant to treatment with methotrexate.1 The study involved 33 sites in
12 countries for a total enrolment of 173
patients. Similar to the etanercept, adalimumab, abatacept and tocilizumab trials, the
study was a randomised withdrawal trial
with the primary outcome defined as JIA
flares in the withdrawal phase. Secondary
outcomes
included
ACRPed50/70/90
responses, clinical remission, pharmacokinetics and safety. In the open-label phase,
89%/79.2%/65.9%/36.4% demonstrated
an ACRPed30/50/70/90 response. At the
end of phase II (week 48) the primary end
point was not met (JIA flares, golimumab
vs placebo: 32/78=41% vs 36/76=47%;
p=0.41).
It is important to consider the reasons
why this trial might not have met its
primary end point. One can postulate on
the possible factors contributing to the
negative results. (1) The long half-life of
golimumab could have led to carry-over
effects in the randomised withdrawal
phase. (2) Disease duration at time of
initiation of golimumab as well as duration and dosing of methotrexate may have
had a differential impact on response to
therapy.12 18 The eligibility criteria specified disease duration of at least 6 months
but disease duration at baseline was not
collected; the proportion of patients on
a dose of 15 mg/m2 subcutaneous methotrexate was not provided. (3) The presence of neutralising antibodies could have
had an effect on efficacy (the number
of patients with high titre neutralising
antibodies was small (n=8) in this study
precluding definitive assessment of the
clinical impact). The other main biological trials2–6 similarly report low prevalence and generally low titre neutralising
antibodies, but there are issues with the
timing of testing, reliability of the assays
and generalisability of the results. The
prevalence and potential clinical significance of antidrug antibodies in primary
and secondary treatment failure to biological agents in paediatric rheumatology
warrants further investigation.
There are no doubt differences in the
pathogenesis of rheumatoid arthritis (RA)
and JIA, at minimum as evidenced by
the absence of circulating autoantibodies
(rheumatoid factor and anti-cyclic-citrullinated peptide(CCP)) in most cases as well
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as the presence of chronic anterior uveitis;
however, there has yet to be a biological
agent that has proven to be ineffective for
use in JIA once its effect has been demonstrated in RA. Similarly, biological agents
found to be effective in the adult spondyloarthropathies have been successful in the
paediatric population with enthesitis-related arthritis,19 20 a forerunner to spondyloarthropathy in later years. Furthermore,
biological agents effective in systemic JIA
have been used successfully in adult-onset
Still’s disease, likely the same disease differentiated essentially by the age of onset.
As highlighted, there are many challenges in conducting typical randomised
controlled trials in paediatric patients
including ethics, acceptability, difficulty in recruiting an adequate sample
size, rarity of disease and standardisation (age, outcome measures, selective
reporting) and alternate trial designs are
not without challenges. It may be time
to rethink the regulatory approach to
approvals of biological agents that have
been documented to be effective in the
adult population. At a minimum, perhaps
approval of a new biological agent for
non-systemic polyarticular course JIA
(that already has proven efficacy in RA)
should only require paediatric trials of
pharmacokinetic and safety to save the
time and expense of a clinical trial only
to have it fail. Alternatively, perhaps, as
shown in systemic JIA,21 the randomised
placebo-controlled trial with early escape
should again be considered. Either
approach will save significant resources
and allow patients to get the treatment
they need in a more expeditious way.
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